Zupion-SR Tablet contains Bupropion 150 mg, an atypical antidepressant primarily indicated for the treatment of major depressive disorder and as an aid in smoking cessation. Bupropion acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), enhancing neurotransmitter activity in the central nervous system, which helps alleviate symptoms of depression and reduce nicotine withdrawal. The sustained-release (SR) formulation ensures gradual drug release, maintaining stable plasma concentrations and improving patient compliance by reducing dosing frequency. Zupion-SR is contraindicated in patients with a history of seizures, eating disorders, or those undergoing abrupt discontinuation of alcohol or sedatives, due to an increased risk of seizures. Common adverse effects include insomnia, dry mouth, headache, and gastrointestinal disturbances, while serious side effects may involve seizures and hypersensitivity reactions. It is essential to monitor patients for neuropsychiatric symptoms and suicidal ideation, especially during initial treatment phases. Dose adjustments may be necessary in patients with hepatic or renal impairment. Zupion-SR should be prescribed with caution in individuals with cardiovascular disease or concomitant medications that lower the seizure threshold. Overall, Zupion-SR offers an effective therapeutic option for depression and smoking cessation when used under appropriate medical supervision.